Collegium Pharmaceutical (COLL) Net Cash Flow Growth (3y) (2017 - 2026)
Collegium Pharmaceutical (COLL) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Collegium Pharmaceutical | 897.87 Mn | 748.55 Mn | 110.29 Mn | -134.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -134.53% |
| Mar 31, 2026 | -26.91% |
| Dec 31, 2025 | 27.06% |
| Sep 30, 2025 | 42.14% |
| Jun 30, 2025 | 9.70% |
| Mar 31, 2025 | 31.17% |
| Dec 31, 2024 | 87.93% |
| Sep 30, 2024 | -125.26% |
| Jun 30, 2024 | -68.55% |
| Mar 31, 2024 | -47.23% |
| Dec 31, 2023 | -62.02% |
| Sep 30, 2023 | -48.54% |
| Jun 30, 2023 | -24.27% |
| Mar 31, 2023 | 57.02% |
| Dec 31, 2022 | 34.72% |
| Sep 30, 2022 | 30.55% |
| Jun 30, 2022 | 5.10% |
| Mar 31, 2022 | -89.46% |
| Dec 31, 2021 | -44.16% |
| Sep 30, 2021 | -52.94% |